Justcurious, I write as a former minor sh who really wants to see Cavatak become a successful weapon against cancer. What in the opinion of yourself -and others is the viability of VLA going it alone?
The reason I ask this question is that VLA is dealing with a monopsony cartel in the pharmaceutical world and like Woolies and Coles, they can exert great pressure on a supplier or potential supplier. To me it seems they could be dragging their feet to allow possible competition to catch -up as it were, to enable them to take advantage of supplier competition to get an anti-cancer drug/virus at the lowest possible price.
As an example of what can happen to a start up facing this industry I refer you to the case of Unilife [UNS].Developed excellent retractable syringe technology designed to meet the requirements of various injectable drugs on a B to B basis [funded by shareholders of course].Admittedly a gungho management style didn't help but overspending on too many devices to meet the future needs of the Pharmas led eventually to the Companies demise.I and many others got our fingers badly burnt.And guess who picked up the IP for next to nothing?
I'd hate to see this Company suffer the same fate. If the BOD is not savvy enough to know how the Pharmaceutical Companies behave as a pack and don't have contingency plans in place-beware. And keep an eye on the shorts-they can act as a bell wether.
donnybrook
VLA Price at posting:
70.0¢ Sentiment: None Disclosure: Not Held
